Randal W. Scott, Director at BridgeBio Pharma, Inc. (BBIO), sold 20,000 shares at $74.34 ($1.5M) on 2026-02-17, disclosed to the SEC on 2026-02-18.
Open-market sale of $1.5M BBIO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $74.34 | 1,900 | $141K | 9.4% |
| 2 | $74.34 | 1,900 | $141K | 9.4% |
| 3 | $75.57 | 4,793 | $362K | 24.0% |
| 4 | $75.57 | 4,793 | $362K | 24.0% |
| 5 | $75.93 | 3,307 | $251K | 16.6% |
| 6 | $75.93 | 3,307 |
| $251K |
| 16.6% |
| Total | $75.46 avg | 20,000 | $1.5M | 100% |
| Filing → |
| BBIO | SELL | 2024-06-05 | $76K | — | Filing → |
| BBIO | SELL | 2024-03-05 | $85K | — | Filing → |
| BBIO | SELL | 2023-12-20 | $80K | — | Filing → |